NOTES-Assisted Laparoscopic Cholecystectomy Surgery (TAS-NOTES)
|First Received Date ICMJE||February 19, 2009|
|Last Updated Date||July 3, 2012|
|Start Date ICMJE||February 2009|
|Primary Completion Date||March 2012 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||post operative pain [ Time Frame: two weeks ]|
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||Complete list of historical versions of study NCT00848146 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
||quality of life [ Time Frame: two weeks ]|
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||NOTES-Assisted Laparoscopic Cholecystectomy Surgery|
|Official Title ICMJE||Natural Orifice Translumenal Endoscopic Surgery (NOTES)-Assisted Laparoscopic Cholecystectomy Surgery|
Refinements in laparoscopic surgery, coupled with advancements in therapeutic flexible endoscopy, have set the stage for surgery to move to even less invasive techniques to treat conditions in the GI tract and peritoneal cavity. Natural orifice translumenal endoscopic surgery (NOTES) offers a means of reducing and ultimately eliminating the need for abdominal incisions to gain access to the peritoneal cavity. In NOTES, a flexible endoscope and accessory instruments are inserted through a natural body orifice and passed through the wall of an organ to reach the abdominal cavity. By reducing or eliminating the need for abdominal incisions, NOTES may provide a least invasive surgical option that can reduce pain, recovery time, complications, and systemic inflammatory response when compared to a laparoscopic surgical approach. In this study, we propose to use the NOTES technique to eliminate the need for a 1.5-2.5 cm umbilical incision.
Hypothesis 1: We hypothesize that a combined endoscopic and laparoscopic approach will be able to eliminate a 1.5 to 2.5 cm infraumbilical incision when performing a laparoscopic cholecystectomy.
Hypothesis 2: Closure of the gastrotomy will be facilitated with the Ethicon TAS system.
In this study, we propose to use a surgical technique that eliminates the need for a 1.5-2.5 cm umbilical incision. All patients will receive pre-operative antibiotics. A Veress needle will be used to create pneumoperitoneum with insufflation of carbon dioxide gas by a standard laparoscopic insufflator. A 5 mm laparoscopic port will be inserted through the abdominal wall in the right mid-abdomen and a 5 mm laparoscope inserted for viewing the abdominal cavity. A flexible endoscope, positioned within a multi-lumen 18 mm therapeutic access device, will be inserted through the mouth and into the stomach. Using commercially available endoscopes, endoscopic instruments and accessories, a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. Additional laparoscopic trocars may be placed through the abdominal wall for laparoscopic instrument insertion to manipulate, retract and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. Intraoperative cholangiogram or laparoscopic ultrasound will be performed at the discretion of the surgeon. Once dissected free, the gallbladder will be removed through the stomach and out of the mouth with the aid of an endoscopic retrieval bag. Commercially available endoscopic clips, or FDA approved tissue anchors will be used to close the gastrotomy. Additionally, the gastrotomy closure will be tested for leaks and laparoscopically oversewn with suture.
Operative and recovery room times as well as hospital length of stay will be collected. During the hospital stay, severity of pain, use of pain medications and complications will be recorded. Patients will be discharged per the standard of practice for a laparoscopic cholecystectomy. All study patients will receive a call from a surgery clinic nurse on post-op day 2 and 7. We will develop a check list that will contain the following (yes/no) elements to be used prior to discharge, on the post-op day 2 and 7 phone calls, and the 2 week post-op clinic visit: pain controlled with meds, nausea, emesis, fever, chills, redness of incisions, drainage from incisions, shortness of breath, chest pain, yellow eyes, dark urine, clay-colored stools. If there are any "yes" responses to this checklist prior to discharge, the patient will not be discharged from the hospital. If there are any "yes" responses to this checklist at the post-op day 2 or 7 phone call, the patient will be advised to immediately come to the GI surgery clinic or go to the nearest emergency room. If there are any "yes" responses to this checklist at the 2 week clinic visit, the patient will undergo the necessary standard of care medical evaluation (labs, tests, etc.) and may be admitted to the hospital. These checklists will be reviewed by one of the investigators, collected and stored in a locked file cabinet.
Patients will return and be evaluated by their surgeon two weeks following their procedure. At this visit, any post-operative complications will be noted in the patient's medical record. Additionally at this visit and at the preoperative visit, patients will complete a standardized Quality of Life (QOL) assessment (i.e., SF-36). Perceived pain levels and type and frequency of pain medications will be recorded in the patient's medical record.
The potential advantages to the patients entered into this study include those mentioned above regarding elimination of post-operative wound infection and hernia but also the lack of abdominal incisions greater than 5 mm in length may reduce pain and recovery time and likely have a cosmetic advantage as well. Potential risks of this study involve the risks of the standard laparoscopic procedure including bleeding, infection, injury to surrounding structures and port/trocar site pain. Potential risks associated with use of flexible endoscopic instruments include esophageal perforation, bleeding and sore throat. In addition, there is the possibility that there may be new, unanticipated complications from this modified surgical technique. Patient risks will be mitigated by having the procedure performed by a surgeon with expertise in both laparoscopic surgery and flexible endoscopy, as well as having involvement of a skilled interventional gastroenterologist if deemed necessary.
This feasibility study will initially evaluate the potential benefit, risks and impact on the patient's quality of life of this modified surgical technique in 10 patients. Once a standardized technique is established and risks are shown to be low, a prospective comparative evaluation is planned to compare this modified technique to the standard laparoscopic approach.
|Study Type ICMJE||Interventional|
|Study Phase||Not Provided|
|Study Design ICMJE||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Intervention ICMJE||Procedure: Endoscopically assisted Laparoscopic Cholecystectomy Surgery
Using endoscopic instruments a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The gallbladder will be removed through the stomach and out of the mouth. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the gastrotomy.
|Study Arms||Experimental: NOTES-Assisted Lap Chole
These patients will undergo an experimental surgical procedure that uses a combination of laparoscopic instruments (i.e., inserted through the skin into the abdominal cavity) and flexible endoscopic instruments (i.e., inserted through the mouth).
Intervention: Procedure: Endoscopically assisted Laparoscopic Cholecystectomy Surgery
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Completion Date||March 2012|
|Primary Completion Date||March 2012 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages||18 Years to 85 Years (Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT00848146|
|Other Study ID Numbers ICMJE||23522
NU IRB# 1452-006
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||Eric Hungness, Northwestern University|
|Study Sponsor ICMJE||Northwestern University|
|Collaborators ICMJE||Ethicon Endo-Surgery|
|PRS Account||Northwestern University|
|Verification Date||July 2012|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP